Author

S. Franz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

G. Simmons· 2 shared A. D. Werts· 1 shared A. M. Healy· 1 shared A. R. Charbit· 1 shared B. Sodeik· 1 shared C. Fischer· 1 shared C. Goffinet· 1 shared C. Schüler· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

G. Simmons

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE-2 in vitro

K. Khanna, W. Raymond, J. Jin, A. R. Charbit, I. Gitlin, M. Tang, A. D. Werts, E. G. Barrett, J. M. Cox, S. M. Birch, R. Martinelli, H. S. Sperber, S. Franz, S. Pillai, A. M. Healy, , J. V. Fahy

Thiol drugs inhibit SARS-CoV-2 infection in vitro and reduce lung injury in vivo, supporting their potential as COVID-19 treatments.

bioRxiv · Dec 8, 2020 · PreprintMicrobiology

Human IFITM3 restricts Chikungunya virus and Mayaro virus infection and is susceptible to virus-mediated counteraction

S. Franz, T. Zillinger, F. Pott, C. Schüler, S. Dapa, C. Fischer, V. Passos, S. Stenzel, F. Chen, K. Döhner, G. Hartmann, B. Sodeik, F. Pessler, G. Simmons, J. F. Drexler, C. Goffinet

This study shows IFITM3 restricts CHIKV and MAYV infection and is counteracted by these viruses, with a variant showing similar antiviral activity to wild-type.

bioRxiv · Sep 11, 2020Microbiology